M H Davidson

Summary

Affiliation: Chicago Center for Clinical Research
Country: USA

Publications

  1. ncbi request reprint Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia
    Michael Davidson
    Chicago Center for Clinical Research, Chicago, Illinois, USA
    Am J Cardiol 89:268-75. 2002
  2. ncbi request reprint A symposium: National Cholesterol Education Program Adult Treatment Panel III: Impact and implementation of the new guidelines. Introduction
    Michael H Davidson
    Chicago Center for Clinical Research, Chicago, Illinois, USA
    Am J Cardiol 89:1C-2C. 2002
  3. ncbi request reprint Strategies to improve Adult Treatment Panel III guideline adherence and patient compliance
    Michael H Davidson
    Chicago Center for Clinical Research, Chicago, Illinois, USA
    Am J Cardiol 89:8C-20C; discussion 20C-22C. 2002
  4. ncbi request reprint Management of hypercholesterolaemia in postmenopausal women
    Michael H Davidson
    Chicago Center for Clinical Research, Illinois 60610, USA
    Drugs Aging 19:169-78. 2002
  5. ncbi request reprint Differential effects of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I are consistent across hypercholesterolemic patient subgroups
    Michael H Davidson
    Chicago Center for Clinical Research, Chicago, Illinois 60610, USA
    Clin Cardiol 26:509-14. 2003
  6. ncbi request reprint Ezetimibe: a novel option for lowering cholesterol
    Michael H Davidson
    Chicago Center for Clinical Research, IL 60610 4324, USA
    Expert Rev Cardiovasc Ther 1:11-21. 2003
  7. ncbi request reprint Combination therapy for dyslipidemia: safety and regulatory considerations
    Michael H Davidson
    Chicago Center for Clinical Research, Rush Medical College, Chicago, Illinois 60612, USA
    Am J Cardiol 90:50K-60K. 2002
  8. ncbi request reprint Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia
    Michael H Davidson
    Chicago Center for Clinical Research, Illinois 60610, USA
    J Am Coll Cardiol 40:2125-34. 2002
  9. ncbi request reprint Efficacy of over-the-counter nutritional supplements
    Michael H Davidson
    Department of Preventive Cardiology, Rush Presbyterian St Luke s Medical Center, 1725 West Harrison Street, Suite 1159, Chicago, IL 60612, USA
    Curr Atheroscler Rep 5:15-21. 2003
  10. ncbi request reprint Lipid management and the elderly
    Michael H Davidson
    Chicago Center for Clinical Research, 515 North State Street, Suite 2700, Chicago, IL 60610
    Prev Cardiol 6:128-33; quiz 134-5. 2003

Detail Information

Publications74

  1. ncbi request reprint Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia
    Michael Davidson
    Chicago Center for Clinical Research, Chicago, Illinois, USA
    Am J Cardiol 89:268-75. 2002
    ..Both treatments were well tolerated...
  2. ncbi request reprint A symposium: National Cholesterol Education Program Adult Treatment Panel III: Impact and implementation of the new guidelines. Introduction
    Michael H Davidson
    Chicago Center for Clinical Research, Chicago, Illinois, USA
    Am J Cardiol 89:1C-2C. 2002
  3. ncbi request reprint Strategies to improve Adult Treatment Panel III guideline adherence and patient compliance
    Michael H Davidson
    Chicago Center for Clinical Research, Chicago, Illinois, USA
    Am J Cardiol 89:8C-20C; discussion 20C-22C. 2002
    ..The use of global risk scoring aids, including the Palm Pilot cholesterol risk calculators, can improve guideline adherence and provide education and motivation to patients to maintain compliance...
  4. ncbi request reprint Management of hypercholesterolaemia in postmenopausal women
    Michael H Davidson
    Chicago Center for Clinical Research, Illinois 60610, USA
    Drugs Aging 19:169-78. 2002
    ..The effects of each type of therapy and potential adverse effects should also be considered...
  5. ncbi request reprint Differential effects of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I are consistent across hypercholesterolemic patient subgroups
    Michael H Davidson
    Chicago Center for Clinical Research, Chicago, Illinois 60610, USA
    Clin Cardiol 26:509-14. 2003
    ..In addition to lowering plasma levels of low-density lipoprotein cholesterol (LDL-C), statins also raise high-density lipoprotein cholesterol (HDL-C)...
  6. ncbi request reprint Ezetimibe: a novel option for lowering cholesterol
    Michael H Davidson
    Chicago Center for Clinical Research, IL 60610 4324, USA
    Expert Rev Cardiovasc Ther 1:11-21. 2003
    ..Ezetimibe can be used in conjunction with a statin at the beginning of therapy, or it can be added if patients do not achieve their LDL-cholesterol goal with statins alone...
  7. ncbi request reprint Combination therapy for dyslipidemia: safety and regulatory considerations
    Michael H Davidson
    Chicago Center for Clinical Research, Rush Medical College, Chicago, Illinois 60612, USA
    Am J Cardiol 90:50K-60K. 2002
    ..This article discusses several safety and regulatory considerations for the use of combination therapy for dyslipidemia...
  8. ncbi request reprint Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia
    Michael H Davidson
    Chicago Center for Clinical Research, Illinois 60610, USA
    J Am Coll Cardiol 40:2125-34. 2002
    ..The purpose of this study was to assess the efficacy and safety of ezetimibe administered with simvastatin in patients with primary hypercholesterolemia...
  9. ncbi request reprint Efficacy of over-the-counter nutritional supplements
    Michael H Davidson
    Department of Preventive Cardiology, Rush Presbyterian St Luke s Medical Center, 1725 West Harrison Street, Suite 1159, Chicago, IL 60612, USA
    Curr Atheroscler Rep 5:15-21. 2003
    ..There is potential evidence for the health benefits of soy protein, tea extracts, policosanol, guggulipids, coenzyme Q10, and L-arginine. There has been a lack of evidence for the health benefits of garlic and antioxidants...
  10. ncbi request reprint Lipid management and the elderly
    Michael H Davidson
    Chicago Center for Clinical Research, 515 North State Street, Suite 2700, Chicago, IL 60610
    Prev Cardiol 6:128-33; quiz 134-5. 2003
    ..This article reviews key issues in the management of hyper-cholesterolemia with respect to coronary heart disease risk reduction in the elderly...
  11. ncbi request reprint Combination lipid-lowering therapy in diabetes
    Michael H Davidson
    Chicago Center for Clinical Research, Rush Presbyterian St Luke s Medical Center, 1725 West Harrison Street, Suite 1159, Chicago, IL 60612, USA
    Curr Diab Rep 3:263-8. 2003
    ..For diabetic patients who require additional LDL lowering, ezetimibe may provide a safe combination to a statin to achieve the LDL goal of less than 100 mg/dL...
  12. ncbi request reprint Rosuvastatin: a highly efficacious statin for the treatment of dyslipidaemia
    Michael H Davidson
    Rush Presbyterian St Luke s Medical Center, Chicago, IL 60612, USA
    Expert Opin Investig Drugs 11:125-41. 2002
    ..A starting dose of 10 mg will reduce LDL-C by approximately 50%, which should adequately treat most patients to within the National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III) goals...
  13. ncbi request reprint A multiple-dose pharmacodynamic, safety, and pharmacokinetic comparison of extended- and immediate-release formulations of lovastatin
    Michael H Davidson
    Chicago Center for Clinical Research, Illinois 60610, USA
    Clin Ther 24:112-25. 2002
    ....
  14. ncbi request reprint The safety and immunogenicity of a CETP vaccine in healthy adults
    Michael H Davidson
    Rush Presbyterian St Luke s Medical Center, Chicago Center for Clinical Research, 515 North State Street, Suite 2700, Chicago, IL 60610, USA
    Atherosclerosis 169:113-20. 2003
    ..CETi-1 is a feasible therapy in humans to induce CETP auto-antibodies. Future research will determine if repeat inoculations will induce a sufficient anti-CETP antibody response to inhibit CETP and increase HDL levels...
  15. ncbi request reprint Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects
    M H Davidson
    Chicago Center for Clinical Research, Ill 60610, USA
    Arch Intern Med 159:1893-900. 1999
    ....
  16. ncbi request reprint Safety profiles for the HMG-CoA reductase inhibitors: treatment and trust
    M H Davidson
    Chicago Center for Clinical Research, Illinois 60610, USA
    Drugs 61:197-206. 2001
    ..Thus, it can be concluded that HMG-CoA reductase inhibitors are well tolerated, effective treatments for hypercholesterolaemia...
  17. ncbi request reprint Colesevelam hydrochloride: a non-absorbed, polymeric cholesterol-lowering agent
    M H Davidson
    Nutrition and Metabolism Research Unit, Chicago Center for Clinical Research, 515 North State Street, Suite 2700, Chicago, IL 60610, USA
    Expert Opin Investig Drugs 9:2663-71. 2000
    ..Colesevelam, recently approved by the US FDA, represents a valuable non-absorbed alternative in the armamentarium against hypercholesterolaemia, both for monotherapy and combination therapy, as an adjunct to diet and exercise...
  18. ncbi request reprint Comparison of the effects of lean red meat vs lean white meat on serum lipid levels among free-living persons with hypercholesterolemia: a long-term, randomized clinical trial
    M H Davidson
    Chicago Center for Clinical Research, IL 60610, USA
    Arch Intern Med 159:1331-8. 1999
    ....
  19. ncbi request reprint Efficacy and safety of an over-the-counter transdermal nicotine patch as an aid for smoking cessation
    M Davidson
    Chicago Center for Clinical Research, Ill 60610 4324, USA
    Arch Fam Med 7:569-74. 1998
    ..To evaluate the efficacy and safety of a transdermal nicotine patch as an aid for smoking cessation in an over-the-counter setting...
  20. ncbi request reprint Rosuvastatin: a highly efficacious statin for the treatment of dyslipidaemia
    Michael H Davidson
    Rush Presbyterian St Luke s Medical Center, 1725 West Harrison Street, Chicago, IL 60612, USA
    Expert Opin Investig Drugs 11:125-41. 2002
    ..A starting dose of 10 mg will reduce LDL-C by approximately 50%, which should adequately treat most patients to within the National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III) goals...
  21. ncbi request reprint Lipid responses to plant-sterol-enriched reduced-fat spreads incorporated into a National Cholesterol Education Program Step I diet
    K C Maki
    Chicago Center for Clinical Research, IL 60610, USA
    Am J Clin Nutr 74:33-43. 2001
    ..Plant sterol esters reduce cholesterol absorption and lower circulating blood cholesterol concentrations when incorporated into the habitual diet...
  22. ncbi request reprint Low-dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low-density lipoprotein cholesterol in patients with primary hypercholesterolemia
    M H Davidson
    The Chicago Center for Clinical Research, Chicago, Illinois, USA
    Clin Cardiol 24:467-74. 2001
    ..CONCLUSIONS: Combination colesevelam and lovastatin was efficacious and well tolerated, resulting in additive decreases in LDL cholesterol levels whether or not both agents were administered simultaneously...
  23. ncbi request reprint Statin trials in progress: unanswered questions
    M H Davidson
    Chicago Center for Clinical Research, Rush Presbyterian-St. Luke's, 515 North State Street, Suite 2700, Chicago, IL 60610, USA
    Curr Atheroscler Rep 3:9-13. 2001
    ....
  24. ncbi request reprint Long-term effects of consuming foods containing psyllium seed husk on serum lipids in subjects with hypercholesterolemia
    M H Davidson
    Chicago Center for Clinical Research, IL 60610, USA
    Am J Clin Nutr 67:367-76. 1998
    ..Although modest, the effect of 10.2 g PSH/d on LDL cholesterol (relative to the control) persisted throughout the 24-wk treatment period, indicating potential for long-term benefit...
  25. ncbi request reprint Efficacy and safety of ezetimibe coadministered with statins: randomised, placebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia
    M H Davidson
    Radiant Research, Chicago, IL 60610 4324, USA
    Int J Clin Pract 58:746-55. 2004
    ..Ezetimibe + statin had a safety profile similar to statin monotherapy. Coadministration of ezetimibe + statin offers a well-tolerated, highly efficacious new treatment strategy for patients with hypercholesterolemia...
  26. ncbi request reprint Safety and tolerability of esterified phytosterols administered in reduced-fat spread and salad dressing to healthy adult men and women
    M H Davidson
    Chicago Center for Clinical Research, Illinois 60610, USA
    J Am Coll Nutr 20:307-19. 2001
    ..0 g/day arm (-13.3%, p < 0.05). DISCUSSION: The results of this study indicate that phytosterol esters are well tolerated and show no evidence of adverse effects at a daily intake of up to 9.0 g of phytosterols for eight weeks...
  27. ncbi request reprint Treatment of the elderly with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors: focus on drug interactions
    M H Davidson
    Chicago Center for Clinical Research, 515 North State Street, Chicago, IL 60610, USA
    J Cardiovasc Pharmacol Ther 6:219-29. 2001
    ..The elderly population, while at high risk for CVD, is currently undertreated. Statins can effectively lower low-density lipoprotein cholesterol levels and lessen the risk of CVD for this population...
  28. ncbi request reprint Reduced treatment success in lipid management among women with coronary heart disease or risk equivalents: results of a national survey
    Benjamin J Ansell
    University of California at Los Angeles, Los Angeles, CA, USA
    Am Heart J 152:976-81. 2006
    ..This survey assessed and compared National Cholesterol Education Program (NCEP) Third Adult Treatment Panel lipid treatment goal achievement for men versus women undergoing treatment of dyslipidemia...
  29. ncbi request reprint Global risk management in patients with type 2 diabetes mellitus
    Michael H Davidson
    Rush University Medical Center, Chicago, Illinois 60612, USA
    Am J Cardiol 99:41B-50B. 2007
    ..Global risk reduction with aggressive low-density lipoprotein reduction and through the additional normalization of glucose levels and blood pressure can help to reduce absolute risk in this very high-risk population...
  30. ncbi request reprint Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients
    Alberico L Catapano
    University of Milan, Milan, Italy
    Curr Med Res Opin 22:2041-53. 2006
    ..To assess the lipid-altering efficacy and safety of ezetimibe/simvastatin single tablet product compared with rosuvastatin at the approved usual starting, next highest, and maximum doses...
  31. ncbi request reprint Combination therapy with ezetimibe and simvastatin to achieve aggressive LDL reduction
    Jennifer G Robinson
    University of Iowa, Lipid Research Clinic, Departments of Epidemiology and Medicine, 200 Hawkins Drive, SE 226 GH, Iowa City, IA 52242, USA
    Expert Rev Cardiovasc Ther 4:461-76. 2006
    ..Ezetimibe 10 mg/simvastatin 80 mg lowers LDL by approximately 60% and has been demonstrated to be superior to the highest doses of atorvastatin and rosuvastatin for lowering LDL and raising high-density lipoprotein...
  32. ncbi request reprint Effects of fenofibrate on atherogenic dyslipidemia in hypertriglyceridemic subjects
    Michael H Davidson
    Department of Cardiology, Rush University Medical College, 60610, USA
    Clin Cardiol 29:268-73. 2006
    ....
  33. pmc A comparison of Canadian and American guidelines for lipid management using data from the National Cholesterol Education Program Evaluation ProjecT Utilizing Novel E-technology (NEPTUNE) II survey
    K C Maki
    Radiant Development, Chicago, Illinois, USA
    Can J Cardiol 22:315-22. 2006
    ..The United States' National Cholesterol Education Program (NCEP) Adult Treatment Panel III and the Canadian Working Group on Hypercholesterolemia and Other Dyslipidemias (CWG) have each issued guidelines for the treatment of dyslipidemia...
  34. ncbi request reprint Cholesterol absorption blockade with ezetimibe
    Peter P Toth
    Director of Preventive Cardiology, Sterling Rock Falls Clinic, Illinois, University of Illnois School of Medicine, Peoria, 61081, USA
    Curr Drug Targets Cardiovasc Haematol Disord 5:455-62. 2005
    ..Ezetimibe is indicated in the management of hyperlipidemia, familial hypercholesterolemia, and sitosterolemia and significantly increases the percentage of patients able to reach their lipid-lowering goals...
  35. ncbi request reprint Striated muscle safety of ezetimibe/simvastatin (Vytorin)
    Michael H Davidson
    Rush University Medical Center, Chicago, Illinois, USA
    Am J Cardiol 97:223-8. 2006
    ..Thus, the clinical trial experience with ezetimibe/simvastatin suggests that ezetimibe does not enhance or aggravate the muscle effects of simvastatin...
  36. ncbi request reprint Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions
    Michael H Davidson
    Rush University, Preventive Cardiology Center, Rush Presbyterian St Luke s Medical Center, 515 State Street, Suite 2700, Chicago, IL, USA
    Expert Opin Drug Saf 5:145-56. 2006
    ..The Action to Control Cardiovascular Risk in Diabetes (ACCORD) study in 10,000 patients with Type 2 diabetes mellitus is testing the efficacy and safety of fenofibrate/statin combination...
  37. ncbi request reprint Effects of a reduced-glycemic-load diet on body weight, body composition, and cardiovascular disease risk markers in overweight and obese adults
    Kevin C Maki
    Radiant Research, Chicago, IL, USA
    Am J Clin Nutr 85:724-34. 2007
    ..Lowering the dietary glycemic load and increasing protein intake may be advantageous for weight management...
  38. ncbi request reprint Safety of aggressive lipid management
    Michael H Davidson
    Radiant Research, Rush University Medical Center, Chicago, Illinois, USA
    J Am Coll Cardiol 49:1753-62. 2007
    ..In order to optimize patient outcomes, clinicians should be aware of specific patient characteristics, such as advancing age, gender, body mass index, or glomerular filtration rate, which predict muscle and hepatic statin toxicity...
  39. ncbi request reprint Is ezetimibe/simvastatin no better than simvastatin alone? Lessons learned and clinical implications
    Michael H Davidson
    University of Chicago Pritzker School of Medicine, Chicago, IL 60610, USA
    Cleve Clin J Med 75:479-82, 486-8, 490-1. 2008
  40. doi request reprint Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study)
    Christie M Ballantyne
    Baylor College of Medicine and Methodist DeBakey Heart and Vascular Center, Houston, Texas, USA
    Am J Cardiol 101:1428-36. 2008
    ..In conclusion, this study showed that NER/S provided additional clinically relevant improvements in multiple lipid parameters and was safe and well tolerated...
  41. ncbi request reprint Effects of high-fiber oat and wheat cereals on postprandial glucose and lipid responses in healthy men
    Kevin C Maki
    Radiant Research, Chicago, IL, USA
    Int J Vitam Nutr Res 77:347-56. 2007
    ..64 +/- 0.91 vs. 3.38 +/- 0.98 hours x mmol/L, p = 0.018). These results suggest that high-fiber oat cereal influenced postprandial triglyceride and free fatty acid levels, which may have implications regarding cardiovascular disease risk...
  42. doi request reprint The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-bl
    Emile R Mohler
    University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
    J Am Coll Cardiol 51:1632-41. 2008
    ..This study examined the effects of darapladib, a selective lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) inhibitor, on biomarkers of cardiovascular (CV) risk...
  43. ncbi request reprint Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study
    Richard H Karas
    Division of Cardiology, Molecular Cardiology Research Institute, Tufts Medical Center, Boston, Massachusetts, USA
    Am J Cardiovasc Drugs 8:69-81. 2008
    ..This fact has focused increased attention on treating abnormalities of non-high-density lipoprotein-cholesterol (non-HDL-C), HDL-C, and triglycerides in national guidelines and has intensified interest in combination therapy...
  44. doi request reprint Reducing the residual risk of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor therapy with combination therapy
    Tamar S Polonsky
    University of Chicago, Pritzker School of Medicine, Chicago, Illinois 60637 1470, USA
    Am J Cardiol 101:27B-35B. 2008
    ..In this article, the authors review the use of combination therapy as a strategy for risk reduction in CAD...
  45. ncbi request reprint Titration patterns with rosuvastatin as compared with other statins in clinical practice: a retrospective observational cohort study using an electronic medical record database
    Kathleen M Fox
    Department of Epidemiology and Preventive Medicine, School of Medicine, University of Maryland, Baltimore, MD, USA
    Clin Ther 29:2385-94. 2007
    ..Lipid management in clinical practice has been suboptimal with a significant proportion of patients not achieving recommended cholesterol levels. A reason for low goal attainment may be the limited use of upward dose titration...
  46. ncbi request reprint Comparison of low-density lipoprotein cholesterol reduction after switching patients on other statins to rosuvastatin or simvastatin in a real-world clinical practice setting
    Kathleen M Fox
    Am J Manag Care 13:S270-5. 2007
    ..The study compared low-density lipoprotein cholesterol (LDL-C) reduction obtained after switching patients on a statin therapy to rosuvastatin or simvastatin in real-world clinical practice...
  47. ncbi request reprint Targeting high-density lipoprotein cholesterol in the management of cardiovascular disease
    Michael H Davidson
    Pritzker School of Medicine, University of Chicago, Chicago, IL, USA
    Am Heart Hosp J 5:210-6. 2007
    ..This article reviews the strategies for targeting HDL cholesterol to optimize outcomes in CHD...
  48. ncbi request reprint Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study
    Michael H Davidson
    Radiant Research, 515 North State Street, Suite 2700, Chicago, IL 60610, USA
    Clin Ther 29:1354-67. 2007
    ..The National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) has identified non-HDL-C as a secondary therapeutic target in these patients, but treatment goals may not be reached with statin monotherapy alone...
  49. ncbi request reprint Application of recent definitions of the metabolic syndrome to survey data from the National Cholesterol Education Program Evaluation Project Utilizing Novel E-Technology (NEPTUNE II)
    Prakash C Deedwania
    University of California San Francisco, School of Medicine, Fresno, CA 93703, USA
    J Cardiometab Syndr 1:295-300. 2006
    ..The metabolic syndrome is common in patients receiving lipid-lowering therapy in an office-based setting. Three recent definitions resulted in similar estimates of its prevalence...
  50. ncbi request reprint Is LDL-C passed its prime? The emerging role of non-HDL, LDL-P, and ApoB in CHD risk assessment
    Michael H Davidson
    Arterioscler Thromb Vasc Biol 28:1582-3. 2008
  51. ncbi request reprint Reducing residual risk for patients on statin therapy: the potential role of combination therapy
    Michael H Davidson
    Rush Medical College, Rush University Medical Center, Chicago, Illinois 60610, USA
    Am J Cardiol 96:3K-13K; discussion 34K-35K. 2005
    ..This article discusses the role of combination therapy in managing CAD and in achieving optional targets in high-risk patient populations...
  52. ncbi request reprint Use of a treatment algorithm to achieve NCEP ATP III goals with atorvastatin
    James M McKenney
    National Clinical Research Inc, 2809 Emerywood Parkway, Ste 140, Richmond, VA 23294, USA
    J Cardiovasc Pharmacol 46:594-9. 2005
    ..Selecting the starting dose of atorvastatin using a treatment algorithm achieves NCEP ATP III LDL-cholesterol goals in the majority of patients and minimizes the need for dose titration...
  53. ncbi request reprint Newer pharmaceutical agents to treat lipid disorders
    Michael H Davidson
    Rush Presbyterian St Luke s Medical Center, 1725 West Harrison Street, Suite 1159, Chicago, IL 60612, USA
    Curr Cardiol Rep 5:463-9. 2003
    ....
  54. ncbi request reprint Niacin: a powerful adjunct to other lipid-lowering drugs in reducing plaque progression and acute coronary events
    Michael H Davidson
    Department of Preventive Cardiology, Rush Presbyterian St Luke s Medical Center, 1725 West Harrison Street, Chicago, IL 60612, USA
    Curr Atheroscler Rep 5:418-22. 2003
  55. ncbi request reprint Efficacy of simvastatin and ezetimibe in treating hypercholesterolemia
    Michael H Davidson
    J Am Coll Cardiol 42:398-9; author reply 399. 2003
  56. ncbi request reprint Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial)
    Peter H Jones
    Baylor College of Medicine, 6565 Fannin Avenue, A 601, Houston, TX 77030, USA
    Am J Cardiol 92:152-60. 2003
    ..0 mmol/L was achieved by 79% to 92% in rosuvastatin groups compared with 52% to 81% in atorvastatin groups. Drug tolerability was similar across treatments...
  57. ncbi request reprint Lipid and apolipoprotein ratios: association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin
    Daniel J Rader
    University of Pennsylvania School of Medicine, Philadelphia 19104, USA
    Am J Cardiol 91:20C-23C; discussion 23C-24C. 2003
    ..001). Mean percent reductions from baseline in the LDL cholesterol/HDL cholesterol ratio were 52%, 39%, and 30% for rosuvastatin 10 mg, simvastatin 20 mg, and pravastatin 20 mg, respectively, in these 2 trials...
  58. ncbi request reprint Food products containing free tall oil-based phytosterols and oat beta-glucan lower serum total and LDL cholesterol in hypercholesterolemic adults
    Kevin C Maki
    Chicago Center for Clinical Research, IL, USA
    J Nutr 133:808-13. 2003
    ..The results of this trial suggest that consumption of a group of low fat, TOP and beta-glucan- containing foods is a useful adjunct in the dietary management of hypercholesterolemia...
  59. ncbi request reprint Effects of simvastatin, an HMG-CoA reductase inhibitor, in patients with hypertriglyceridemia
    Jonathan Isaacsohn
    Metabolic and Atherosclerosis Research Center, Cincinnati, Ohio, USA
    Clin Cardiol 26:18-24. 2003
    ....
  60. ncbi request reprint Cholesterol-lowering drugs bring benefits to high-risk populations even when LDL is normal
    Lynne T Braun
    The Rush Heart Institute, Rush Presbyterian St Luke s Medical Center, and College of Nursing Rush University, Chicago, Illinois, USA
    J Cardiovasc Nurs 18:44-9; quiz 75-6. 2003
    ..The conclusion was that all high-risk patients with LDL > or = 100 mg/dL should be treated with drug therapy with the goal of reducing LDL to < 100 mg/dL...
  61. ncbi request reprint Consumption of diacylglycerol oil as part of a reduced-energy diet enhances loss of body weight and fat in comparison with consumption of a triacylglycerol control oil
    Kevin C Maki
    Chicago Center for Clinical Research, Chicago, IL 60610, USA
    Am J Clin Nutr 76:1230-6. 2002
    ..Diacylglycerol is a natural component of edible oils that has metabolic characteristics that are distinct from those of triacylglycerol...
  62. ncbi request reprint Effect on high-density lipoprotein cholesterol of maximum dose simvastatin and atorvastatin in patients with hypercholesterolemia: results of the Comparative HDL Efficacy and Safety Study (CHESS)
    Christie M Ballantyne
    Baylor College of Medicine, Houston, Tex 77030, USA
    Am Heart J 146:862-9. 2003
    ..Previous studies have shown that effects on high-density lipoprotein cholesterol (HDL-C) may differ among statins...
  63. ncbi request reprint Lipid responses in mildly hypertriglyceridemic men and women to consumption of docosahexaenoic acid-enriched eggs
    Kevin C Maki
    Radiant Research Chicago, 515 N State Street, Suite 2700, Chicago, IL 60610, USA
    Int J Vitam Nutr Res 73:357-68. 2003
    ..ordinary eggs (-12.3 vs. 2.1%; p = 0.027), and there was a greater increase for HDL cholesterol in the DHA-enriched vs. ordinary egg group (5.0 vs. 1.1%; p = 0.040)...
  64. ncbi request reprint Biologic therapies for dyslipidemia
    Michael H Davidson
    Department of Preventive Cardiology, Rush University Medical Center, 1725 West Harrison Street, Suite 1159, Chicago, IL 60612, USA
    Curr Atheroscler Rep 6:69-72. 2004
    ..Gene therapies to reduce low-density lipoproteins and increase high-density lipoproteins are on the horizon, but the ability to safely prolong gene expression in humans will require the development of novel vectors...
  65. ncbi request reprint Efficacy and safety profile of fenofibrate-coated microgranules 130 mg, with and without food, in patients with hypertriglyceridemia and the metabolic syndrome: an 8-week, randomized, double-blind, placebo-controlled study
    Michael H Davidson
    Radiant Research Inc, Chicago, IL 60610, USA
    Clin Ther 27:715-27. 2005
    ..There is a need for new formulations that have improved bioavailability and eliminate the requirement for administration with food...
  66. ncbi request reprint Effects of raloxifene and low-dose simvastatin coadministration on plasma lipids in postmenopausal women with primary hypercholesterolemia
    William Insull
    Lipid Research Clinic, Baylor College of Medicine and The Methodist Hospital, Houston, TX 77030 2711, USA
    Metabolism 54:939-46. 2005
    ....
  67. ncbi request reprint Simvastatin plus ezetimibe: combination therapy for the management of dyslipidaemia
    Peter P Toth
    Sterling Rock Falls Clinic, Sterling, Illinois, USA
    Expert Opin Pharmacother 6:131-9. 2005
    ..This combination increases the likelihood of therapeutic success in patients with dyslipidaemia...
  68. ncbi request reprint High-dose statins in acute coronary syndromes
    Michael H Davidson
    JAMA 293:38; author reply 38-9. 2005
  69. ncbi request reprint Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin
    Peter H Jones
    Baylor College of Medicine, Houston, Texas 77030, USA
    Am J Cardiol 95:120-2. 2005
    ..The findings suggest that the use of fenofibrate in combination with statins results in fewer reports of rhabdomyolysis per million prescriptions dispensed than does the use of gemfibrozil...
  70. ncbi request reprint Rosuvastatin safety: lessons from the FDA review and post-approval surveillance
    Michael H Davidson
    Rush Medical College, Rush University Medical Center, Chicago, Illinois, USA
    Expert Opin Drug Saf 3:547-57. 2004
    ..In the post-marketing surveillance for rosuvastatin, there have been reports of rhabdomyolysis, but the incidence rate, when corrected for prescription utilisation, is similar to other statins following initial approval...
  71. ncbi request reprint Combination therapy in the management of complex dyslipidemias
    Michael H Davidson
    Rush Medical College, Rush University Medical Center, Chicago, Illinois, USA
    Curr Opin Lipidol 15:423-31. 2004
    ..This review discusses the need for comprehensive management of all abnormalities in a given patient's lipoprotein profile and for the use of combinations of anti-lipidemic medications, when indicated...
  72. ncbi request reprint Therapeutic interventions targeted at the augmentation of reverse cholesterol transport
    Peter P Toth
    Sterling Rock Falls Clinic, Sterling, Illinois 61081, USA
    Curr Opin Cardiol 19:374-9. 2004
    ..This review summarizes the pathway of RCT and the currently available means by which investigators are attempting to modulate HDL levels and increase rates of RCT...
  73. ncbi request reprint A multicenter, randomized, double-blind clinical trial comparing the low-density lipoprotein cholesterol-lowering ability of lovastatin 10, 20, and 40 mg/d with fluvastatin 20 and 40 mg/d
    Michael H Davidson
    Radiant Research Chicago, Chicago, Illinois 60610, USA
    Clin Ther 25:2738-53. 2003
    ..The available statin drugs have similar pharmacodynamic properties but are not equal in low-density lipoprotein cholesterol (LDL-C)-lowering efficacy...
  74. ncbi request reprint A look to the future: new treatment guidelines and a perspective on statins
    Michael H Davidson
    Chicago Center for Clinical Research and Rush Presbyterian St Luke s Medical Center, Chicago, Illinois 60610 4324, USA
    Am J Med 112:34S-41S. 2002
    ..Increased potency of LDL cholesterol-lowering drugs would be of value in enabling more patients to achieve goals...